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Abstract
Purpose of Review Chronic total occlusion (CTO) of the coronary arteries is a significant clinical problem and has traditionally
been treated by medical therapy or coronary artery bypass grafting. Recent studies have examined percutaneous coronary
intervention (PCI) as an alternative option.
Recent Findings This systematic review and meta-analysis compared medical therapy to PCI for treating CTOs.
Summary PubMed and Embase were searched from their inception toMarch 2019 for studies that comparedmedical therapy and
PCI for clinical outcomes in patients with CTOs. Quality of the included studies was assessed by Newcastle–Ottawa scale. The
results were pooled byDerSimonian and Laird random- or fixed-effect models as appropriate. Heterogeneity between studies and
publication bias was evaluated by I2 index and Egger’s regression, respectively. Of the 703 entries screened, 17 studies were
included in the final analysis. This comprised 11,493 participants. Compared to PCI, medical therapy including randomized and
observational studies was significantly associatedwith higher risk of all-cause mortality (risk ratio (RR) 1.99, 95%CI 1.38–2.86),
cardiac mortality (RR 2.36 (1.97–2.84)), and major adverse cardiac event (RR 1.25 (1.03–1.51)). However, no difference in the
rate of myocardial infarction and repeat revascularization procedures was observed between the two groups. Univariate meta-
regression demonstrated multiple covariates as independent moderating factors for myocardial infarction and repeat
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revascularization but not cardiac death and all-cause mortality. However, when only randomized studies were included, there was
no difference in overall mortality or cardiac death. In CTO, when considering randomized and observational studies, medical
therapy might be associated with a higher risk of mortality and myocardial infarction compared to PCI treatment.
Keywords Chronic total occlusion .Mortality . Adverse outcomes
Introduction
Achronic total occlusion (CTO) is characterized by the complete
or near complete occlusion of a coronary artery with no or min-
imal downstream flow (TIMI flow grade 0 or 1) for a period
longer than 3 months [1]. Among patients with coronary heart
disease who are referred for coronary angiography, a large pro-
portion ranging from 18 to 52% are found to have CTOs [2–4].
However, only a small proportion of these patients subsequently
undergo percutaneous coronary intervention (PCI) [2, 5] with
approximately one-tenth of CTO patients in North America un-
dergoing PCI in the end [3, 6, 7]. Therefore, despite the rising
popularity of percutaneous intervention for this group of CTO
patients, the vast majority are either treated with medical therapy
or coronary artery bypass grafting (CABG) [6]. However, it is
recognized that patients with CTOs have a poorer prognosis
when compared to those with coronary disease but without
CTOs [8, 9]. This is often exacerbated by the fact that many
patients with CTO tend to be asymptomatic, which leads to a
delay in the diagnosis, investigations, and subsequent treatment
[3] which may partly at least explain the broad prevalence range.
Hence, despite guidelines [1, 10, 11] recommending consid-
eration of PCI in patients with CTO to improve survivability and
quality of life, the prevalence of PCI in CTO patients remains
low. This trend is potentially further reinforced by the 2016
EXPLORE trial [12].Observation and randomized studies appear
to disagree with the potential benefit of PCI [13–15, 16•, 17••, 18,
19••]. The issue thus ofwhether PCI ormedical therapy should be
the preferred management option in patients with CTOs remains
controversial. This is also further compounded by potential sex-
based differences in CTO management [20]. As such, this sys-
tematic review and meta-analysis seeks to combine all available
cohort studies involving head-to-head comparison between PCI
and medical therapy in CTO patients to offer a more comprehen-
sive understanding. Further multivariate meta-regression analysis
has also been used to help identify covariates that can potentially
moderate outcome measures between the two interventions.
Methods
Search Strategy, Inclusion and Exclusion Criteria
This study was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement. PubMed and Embase were searched for
studies that compare medical therapy to PCI in patients with
CTO. The following search terms were used for both data-
bases: [(chronic total occlusion) AND (((percutaneous coro-
nary intervention) OR (revascularization)) AND ((optimal
medical therapy) OR (medical therapy)))]. The search period
was from the beginning of the database through to March 1,
2019 without language restrictions. Both fully published stud-
ies and abstracts were used. The following inclusion criteria
were used: (1) studies involving patients with CTO requiring
either medical therapy or PCI; (2) measured and compared the
difference in outcome between the two procedures, medical
therapy and PCI. These outcomes assessed included all-cause
mortality, cardiac death, cerebral vascular accident (CVA),
myocardial infarction (MI), repeated revascularization, major
adverse cardiac event (MACE), andmajor adverse cardiac and
cerebrovascular events (MACCEs). MACE was defined as a
composite of non-fatal stroke, non-fatal MI, and cardiovascu-
lar death, whereas MACCEwas defined as a composite of all-
cause mortality, MI, stroke, or ischemia-driven target vessel
revascularization.
The Newcastle–Ottawa Quality Assessment Scale (NOS)
and Cochrane risk of bias tool were used for quality assess-
ment of the included studies. The NOS system evaluated the
categories of study participant selection, results comparability,
and quality of the outcomes. Specifically, the following char-
acteristics were assessed: (1) representativeness of the ex-
posed cohort; (2) selection of the non-exposed cohort; (3)
ascertainment of exposure; (4) demonstration that outcome
of interest was not present at the start of study; (5) compara-
bility of cohorts based on study design or analysis; (6) assess-
ment of outcomes; (7) follow-up periods that were sufficiently
long for outcomes to occur; (8) adequacy of follow-up of
cohorts. This scale varied from zero to nine stars, which indi-
cated that studies were graded as poor quality if the score was
< 5, fair if the score was 5 to 7, and good if the score was > 8.
Studies with a score equal to or higher than 6 were included.
The details of the NOS quality assessment and Cochrane risk
of bias assessment for randomized controlled trials are shown
in Supplementary Table 1 and Supplementary Fig. 1.
Data Extraction and Statistical Analysis
Data from different studies were entered in pre-specified
spreadsheets in Microsoft Excel. All potentially relevant
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studies were retrieved as complete manuscripts, which were
assessed fully to determine their compliance with the inclu-
sion criteria. We extracted the following data from the includ-
ed studies: (1) publication details: last name of first author,
publication year, and locations; (2) study design; (3) out-
come(s); (4) characteristics of the population including sample
size, gender, age, and number of subjects. Two reviewers
(K.H.G.W. and K.H.C.L) reviewed each included study inde-
pendently. Disagreements were resolved by adjudication with
input from a third reviewer (G.T.).
Heterogeneity across studies was determined using
Cochran’s Q value and the I2 statistic from the standard χ2
test. Cochran’s Q value is the weighted sum of squared differ-
ences between individual study effects and the pooled effect
across studies. The I2 statistic from the standard χ2 test de-
scribes the percentage of variability in the effect estimates
resulting from heterogeneity. I2 > 50% was considered to re-
flect significant statistical heterogeneity. The random-effects
model using the inverse variance heterogeneity method was
used with I2 > 50%. To locate the origin of the heterogeneity,
sensitivity analysis excluding one study at a time was also
performed. Funnel plots showing standard errors or precision
against the logarithms of the odds ratio were constructed. The
Begg and Mazumdar rank correlation test and Egger’s test
were used to assess for possible publication bias. Possible
associations between population co-variables and study out-
comes were explored using multivariate meta-regression. To
account for missing data, we used mean imputation (< 10%
missing) or random imputation (> 10% missing). All statisti-
cal analysis was conducted using Review Manager 5.3 for
MacOS and Comprehensive Meta-Analysis (CMA) version
3.0 (Biostat, Inc., Englewood, NJ, USA). Statistical signifi-
cance was set as P value of less than 0.05.
Results
Patient Baseline Characteristics
A flow diagram detailing the search and study selection process
is illustrated in Fig. 1. In the final meta-analysis, a total of 15
cohort studies and 3 randomized controlled trials involving
11,928 patients between 2011 and 2019 met our selection
criteria for inclusion [13–15, 16•, 17••, 18, 19••, 21–31]. Two
studies included the same population [22, 31] and therefore we
only included the most recent one [31] reducing our number of
studies to a total of 17, involving 11,493 patients. Themean age
of the included population was 57.4 years, of themajority being
male (81.8%). The baseline characteristics of all patients and
follow-up duration based on individual studies are summarized
in Table 1. However, only the baseline characteristics for 13
(out of 17) studies were available for inclusion in Table 1 [13,
14, 16•, 17••, 18, 19••, 21–25, 27, 29, 31]. This is due to the
lack of sufficient data provided by the remaining four studies
[15, 26, 28, 30]. Furthermore, the baseline characteristics in-
cluded in three studies (*) utilized that of the overall population
as the studies pooled the baseline characteristics of two or more
intervention groups (e.g., CABG and PCI) together [23, 25, 27]
(Table 1). Nonetheless, sufficient intervention-specific data was
still provided by all 17 studies for effective pooling of outcome
measures. Outcome measures pooled in this meta-analysis in-
clude (1) all-cause mortality, (2) cardiac death, (3) CVA/stroke,
(4) MI, (5) repeat revascularization, (6) MACE, and (7)
MACCE.
Medical Therapy Versus PCI in CTO Patients: All-Cause
Mortality
A total of 14 out of 17 studies reported all-cause mortality in
CTO patients after medical therapy or PCI [13–15, 16•, 17••,
18, 19••, 23–27, 30, 31]. Of these, only two studies reported in
favor of medical therapy [15, 19••] while the remaining 12
reported in favor of PCI. Pooled analysis of all the included
studies demonstrated that patients with CTO treated withmed-
ical therapy have a significantly higher risk of all-cause mor-
tality when compared to the PCI group (RR 1.99, 95% CI
1.38–2.86, P = 0.0002; Fig. 2a). However, what is important
to recognize here is that there is a significant disagreement
with regard to the observational and randomized studies.
The observational studies significantly favor PCI (RR 2.09,
1.40–3.10, P = 0.0003) while the randomized studies showed
a non-significant improvement in mortality (RR 1.41, 0.77–
2.61, P = 0.27), indicating that perhaps the current random-
ized studies do not have sufficient power to confirm a benefit,
which is smaller than what is observed in the cohort studies. I2
was 89% across all studies, indicating a high degree of het-
erogeneity. In order to locate the origin of the heterogeneity,
sensitivity analysis excluding one study at a time was
572 and 131 publicaons were 
retrieved from PubMed and 
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Fig. 1 PRISMA flow diagram for the study selection process
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performed. Doing so did not significantly alter the overall
heterogeneity. In addition, the results of Egger’s test showed
no evidence of publication bias (Egger’s regression test P =
0.13; Fig. 3a).
Medical Therapy Versus PCI in CTO Patients: Cardiac
Mortality
A total of 11 out of 17 studies reported cardiac mortality in
CTO patients [13, 16•, 17••, 19••, 21, 23–26, 29, 31]. All
studies included favored the use of PCI apart from Werner
et al. [19••]. Pooled analysis of the included studies demon-
strated that patients with CTO treated medical therapy had
significantly higher risk of cardiac mortality when compared
to the use of PCI (RR 2.36, 95% CI 1.97–2.84, P < 0.00001;
Fig. 2b). However, the discrepancy between observation and
randomized studies existed.While in observation studies there
was a very positive improvement seen with PCI (RR 2.42,
95% CI 2.00–2.91, P < 0.00001), there was no significant
difference observed with the randomized controlled trials
(RCTs) (RR 1.57, 95% CI 0.70–3.51, P = 0.27) .
Nonetheless, the relative risk of 1.57 could still suggest that
the RCT even when pooled remained underpowered. I2 was
23% across all studies, indicating a low degree of heterogene-
ity. Furthermore, results from Egger’s test showed no evi-
dence of publication bias (Egger’s regression test P = 0.92;
Fig. 3b).
Medical Therapy Versus PCI in CTO Patients:
Myocardial Infarction
A total of 10 studies reported MI as an outcome in CTO
patients undergoing either medical therapy or PCI [13,
17••, 19••, 21, 23–26, 29, 31]. Three out of 10 studies
reported in favor of medical therapy [17••, 19••, 23].
Pooled analysis of the included studies showed that med-
ical therapy was not significantly associated with a higher
risk of MI when compared to the PCI group (RR 1.65,
95% CI 0.97–2.78, P = 0.06; Fig. 2c). However, when
only RCTs were considered, medical therapy showed a
non-statistical improvement over PCI (RR 0.73, 95% CI
0.44–1.19, P = 0.21). Significance was only achieved dur-
ing pooled analysis of observational studies, favoring the
PCI group (RR 2.04, 95% CI 1.31–3.20, P = 0.002). I2
was 74% across all studies, indicating a high degree of
heterogeneity. Sensitivity analysis excluding one study at
a time was performed to locate the origin of the hetero-
geneity which did not significantly alter the overall het-
erogeneity. Results from the Egger’s test showed no evi-
dence of publication bias (Egger’s regression test P =
0.95; Fig. 3c).
Medical Therapy Versus PCI in CTO Patients: Repeated
Revascularization
A total of nine studies were included for reporting repeated
revascularization in CTO patients with either medical therapy
or PCI [13, 16•, 17••, 18, 21, 23, 24, 26, 31]. Of these, five
studies reported in favor of medical therapy [13, 16•, 17••, 21,
26]. A pooled analysis of the included studies demonstrated
that the use of medical therapy is associated with lower risk of
repeat revascularization (RR 0.93, 95% CI 0.67–1.29, P =
0.67; Fig. 2d). While observational studies showed a non-
statistical preference for OMT (RR 0.85, 95% CI 0.59–1.21,
P = 0.36), the randomized studies showed a non-statistical re-
duction of revascularization with PCI (RR 1.87, 95%CI 0.41–
8.58, P = 0.42). I2 was 84% across all studies, indicating a
high degree of heterogeneity. Sensitivity analysis excluding
one study at a time was performed to locate the origin of the
heterogeneity, which did not significantly alter the overall het-
erogeneity. Results from Egger’s test showed no evidence of
publication bias (Egger’s regression test P = 0.24; Fig. 3d).
Medical Therapy Versus PCI in CTO Patients: Major
Adverse Cardiovascular Event
A total of 10 studies reported MACE in CTO patients [13, 15,
17••, 18••, 19••, 21, 23, 26, 28, 31]. Of these, only three out of
eight studies supported the use of medical therapy. A pooled
analysis of the included studies illustrated that the use of PCI
tended to lower risk of MACE when compared to medical
therapy (RR 1.25, 95% CI 1.03–1.51, P = 0.03; Fig. 2e).
Both observational studies (RR 1.25, 95% CI 1.01–1.56, P=
0.0004 ) and randomized trials (RR 1.38, 95% 0.73–2.60, P =
0.33) favored PCI in terms of MACE outcomes. Furthermore,
I2 was 76% across all studies, indicating a high degree of
heterogeneity. Sensitivity analysis excluding one study at a
time was performed to locate the origin of the heterogeneity.
Doing so did not significantly alter the overall heterogeneity.
However, results from Egger’s test showed no evidence of
publication bias (Egger’s regression test P = 0.36; Fig. 3e).
Medical Therapy Versus PCI in CTO Patients: Cerebral
Vascular Accident/Stroke
Regarding CVA/stroke, only 3 out of 14 studies were
found to report this outcome in CTO patients [13, 24,
29]. All three studies reported in favor of PCI over med-
ical therapy. A pooled analysis further supported this,
showing that medical therapy has more than twice the
risk of causing a CVA/stroke compared to PCI (RR
2.10, 95% CI 0.84–5.25, P = 0.11; Fig. 2f). However,
this result was not statistically significant. I2 was 0%
across all studies, indicating a lack of heterogeneity.
Curr Atheroscler Rep           (2019) 21:42 Page 5 of 12    42 
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Results from Egger’s test showed no evidence of publi-
cation bias (Egger’s regression test P = 0.22).
Medical Therapy Versus PCI in CTO Patients: MACCE
Lastly, the outcome of MACCE was only reported in two
studies [24, 29]. Both studies individually favored the
use of PCI to avoid such events, which was supported
by a pooled analysis (RR 2.47, 95% CI 1.52–4.02, P =
0.0003; Fig. 2g). I2 was 56% across all studies, indicat-
ing a moderate level of heterogeneity. However, an
exclude-one sensitivity analysis could not be done, as
there are only two studies involved. Similarly, Begg’s
and Egger’s analysis could not be used due to the limited
number of studies involved.
Univariate Meta-Regression Analysis of All Outcome
Measures
A univariate meta-regression analysis was conducted
using all common covariates across the 17 studies in-
cluded for four outcome measures, which were all-
cause mortality, cardiac death, MI, and repeat revascular-
ization. CVA/stroke, MACE, and MACCE outcomes
were omitted from regression analysis due to a lack of
reporting from relevant articles. Covariates used were
mean age, male sex, hypertension, diabetes mellitus, dys-
lipidemia, smoking, prior PCI, LAD lesion, and calcifi-
cation. Results of the meta-regression are shown in
Table 2 accordingly. No variables were found to indepen-
dently moderate all-cause mortality and cardiac death
outcomes. However, mean age, hypertension, smoking,
LAD lesion, and the presence of calcification were also
found to be a significant moderator of MI while repeat
revascularization was moderated by male gender, diabe-
tes mellitus, smoking, and prior PCI. Apart from these,
none of the other factors moderated cardiac death, MI,
repeat revascularization, or all-cause mortality outcomes.
Slope coefficients did not differ significantly from zero
(P > 0.05).
Discussion
This systematic review and meta-analysis included 17 cohort
studies with a total of 11,493 patients, comparing the use of
medical therapy and PCI in patients with known CTO. A total
of seven outcomes including all-cause mortality, cardiac
death, MI, repeat revascularization, MACE, CVA/stroke, and
MACCE were assessed. A subsequent univariate meta-
regression was also conducted to evaluate the impact of co-
variates on outcome measures. Our pooled analysis found a
statistically significant association between PCI and lower risk
of all-cause mortality, cardiac death, MI, MACE, and
MACCE when compared to medical therapy. However, this
was driven predominantly by the observational cohorts. The
randomized studies showed a potential improvement with PCI
in overall mortality, cardiac death, repeat revascularization,
andMACE; however, no statistical significance was achieved.
PCI tended to reduce CVA/stroke outcomes when compared
to medical therapy, but the results did not reach significance,
which may be due to the limited sample size. On the other
hand, MACE which included admission for heart failure and
non-fatal strokes was favored by PCI. A non-significant re-
duced risk of repeat revascularization was found to be associ-
ated with medical therapy (P > 0.05). This is likely due to
further activation of the inflammatory pathway, which leads
to the development of intimal hyperplasia and subsequent re-
stenosis following PCI [32]. In our univariate regression anal-
ysis, there were no significant moderators of all-cause mortal-
ity and cardiac death. This is not in keeping with a large
Swedish study involving 14,441 patients, which reported that
presence of a CTO was associated with the highest risk of
mortality in patients less than 60 years of age compared to
the low risk found in octogenarians [33]. However, the lack
of association between diabetes and sex is supported by an-
other study [33]. Interestingly, our univariate analysis also
showed hypertension, dyslipidemia, and smoking to be non-
significantly linked with all-cause mortality. As for MI, it is
surprising that diabetes mellitus was found to be a non-
significant moderator given the extensive literature supporting
this correlation [34] while mean age, hypertension, smoking,
having LAD lesions, and calcification were significant
moderators.
Our findings differ from those of a previous meta-
analysis comparing medical therapy and PCI in patients
with stable coronary artery disease. The latter reported
that PCI was not significantly better than optimal medi-
cal therapy in reducing risk of all-cause mortality, cardi-
ac death, and MI [35]. Similar findings were noted in the
landmark Courage Trial where PCI was not found to be
superior to medical therapy but CTO patients were not
represented in this study and patients would receive more
intense medical therapy than what would be expected in
reality [36]. Another meta-analysis confirmed that
Fig. 2 (a) Forest plots comparing risk of all-cause mortality events
between OMT and PCI in patients with CTO. (b) Forest plots
comparing risk of cardiac death between OMT and PCI in patients with
CTO. (c) Forest plots comparing risk of CVA/stroke events between
OMT and PCI in patients with CTO. (d) Forest plots comparing risk of
myocardial infarction between OMT and PCI in patients with CTO. (e)
Forest plots comparing risk of repeated revascularization events between
OMT and PCI in patients with CTO. (f) Forest plots comparing risk of
MACE events between OMT and PCI in patients with CTO. (g) Forest
plots comparing risk of MACCE events between OMT and PCI in
patients with CTO
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Fig. 2 continued.
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successful PCIs in CTO patients pertain to higher long-
term survival along with reduced risk of developing
subsequent MI [37]. Recently, a similar meta-analysis
looking only into five articles stated that the PCI was
significantly associated with reduced risk of all-cause
mortality, cardiac death, and MACE in CTO patients.
This result was further supported in their “infarct-relat-
ed area” subgroup analysis [38]. In contrast, our meta-
analysis utilized 17 studies with a significantly greater
patient population. As such, our results favoring PCI in
CTO should be interpreted in the knowledge that this
is driven mainly by the outcomes in the observational
cohorts and that the RCT failed to reach significance.
Nonetheless, even in the RCT, a non-significant trend
in benefit was seen with PCI groups indicating perhaps
that more RCTs are needed for a definite answer.
Despite this, our meta-analysis suggests that at the
very least, there is no evidence to advice against PCI
in CTO at present and possibly there might be some
benefit.
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Fig. 3 (a) Trim-and-fill funnel plots with Egger’s regression test of all-
cause mortality comparing between OMT and PCI in patients with CTO.
(b) Trim-and-fill funnel plots with Egger’s regression test of cardiac death
comparing between OMTand PCI in patients with CTO. (c) Trim-and-fill
funnel plots with Egger’s regression test of CVA/stroke comparing
between OMT and PCI in patients with CTO. (d) Trim-and-fill funnel
plots with Egger’s regression test of MI comparing between OMT and
PCI in patients with CTO. (e) Trim-and-fill funnel plots with Egger’s
regression test of repeated revascularization comparing between OMT
and PCI in patients with CTO
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Limitations
A moderate to high degree of heterogeneity was identified
during analysis of some outcome measures and we thus
performed an exclude-one sensitivity analysis to locate
the source of heterogeneity and rectify this. In addition,
one of the areas of growing interest in CTO PCI work is
to appropriately select patients by demonstrating objective
evidence of reversible ischemia corresponding to the ter-
ritory of the CTO, rather than simply relying on angina as
a marker for this [39]. Unfortunately, the inclusion criteria
from the studies used included “angina or reversible is-
chemia.” Therefore, we were not able to consider a spe-
cific subgroup of patients who had evidence of reversible
ischemia on functional testing and viable myocardium.
Finally, we have considered the observational and
randomized studies together in the analysis but also sep-
arately. Although the observational studies favored the
PCI quite significantly, this was not statistically seen
when only the fewer randomized studies were considered;
this indicates, however, that a true beneficial effect could
well have been observed if more randomized studies were
available to meta-analyze.
Future Directions
The unmet clinical question is whether randomized studies in
patients who have objective evidence of reversible ischemia,
which can also be quantified, might benefit from PCI.
Although it can be expected that patients with a higher burden
of reversible ischemia and higher percentage of viable
Table 2 Multivariate meta-
regression analysis of outcome
measures
Univariate meta-regression
Variable Slope coefficient SE Z value P value 95% CI
Lower limit Upper limit
All-cause mortality
Mean age (years) − 0.0601 0.109 − 0.553 0.580 − 0.273 0.153
Male gender − 0.969 3.102 − 0.312 0.755 − 7.048 5.111
Hypertension − 1.628 1.849 − 0.881 0.378 − 5.251 1.995
Diabetes mellitus 0.0376 1.558 0.0241 0.981 − 3.016 3.091
Dyslipidemia − 1.086 0.877 − 1.239 0.215 − 2.804 0.632
Smoking 0.933 1.082 0.863 0.388 − 1.187 3.054
Cardiac death
Mean age (years) 0.0799 0.0523 1.529 0.126 − 0.0225 0.182
Male gender 1.049 1.877 − 2.629 0.576 − 2.629 4.728
Hypertension 1.057 1.262 0.837 0.402 − 1.417 3.532
Diabetes mellitus 0.692 0.893 0.775 0.438 − 1.058 2.443
Dyslipidemia 0.0645 0.613 0.105 0.916 − 1.137 1.266
Myocardial infarction − 0.0875 0.810 − 0.108 0.914 − 1.674 1.499
Myocardial infarction
Mean age (years)* 0.257 0.0517 4.969 < 0.0001 0.155 0.358
Male gender − 1.504 5.000 − 0.301 0.764 − 11.301 8.293
Hypertension* 8.026 2.275 3.528 0.000419 3.567 12.486
Diabetes mellitus 1.106 3.115 0.355 0.722 − 4.999 7.212
Smoking* 4.611 1.023 4.506 < 0.0001 2.605 6.617
LAD lesion* 4.907 2.481 1.978 0.0480 0.0440 9.769
Calcification* − 6.476 3.751 − 1.726 0.0843 − 13.828 0.876
Repeat revascularization
Mean age (years) − 0.01 0.133 − 0.751 0.452 − 0.361 0.161
Male gender* 6.288 2.243 2.803 0.00506 1.891 10.684
Hypertension − 2.913 2.107 1.383 0.167 − 1.216 7.043
Diabetes mellitus* 2.808 1.0142 2.769 0.00563 0.820 4.796
Smoking* − 2.388 0.605 − 3.950 < 0.0001 − 3.573 − 1.203
Prior PCI* 4.151 1.775 2.339 0.0193 0.673 7.630
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myocardium are likely to benefit more from percutaneous
intervention, new evidence is needed to answer this question
[40].
Conclusions
The use of PCI in patients with CTO was found to be associ-
ated with lower risk of all outcome measures except repeat
revascularization, a result driven predominantly by the obser-
vational cohorts as the randomized studies appeared to show a
smaller benefit but were underpowered to statistically confirm
that. However, statistically significant results were seen only
for all-cause mortality, cardiac death, MI, MACE, and
MACCE in pooled analysis and not in the RCT-specific sub-
group analysis. Our results suggest that PCI could therefore be
considered in the CTO in patients with angina or evidence of
reversible ischemia. Larger randomized clinical trials can ad-
dress an individualized personalized approach incorporating
the risk and complexity associated with CTO PCI, the burden
of ischemia, and myocardial viability.
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